🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Bio-Techne Corporation TECH SPXR3KPHARMA

Healthcare · Biotechnology · United States
https://www.bio-techne.com
Company Profile ↓
$72.43
+33.19% 1Y
Mkt Cap$11.29B
P/E103.47
P/B5.43
Div. Yield0.44%
52W High$72.47
52W Low$43.17
Book Value$13.32
EPS (TTM)$0.70

Company Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 10.0% CAGR over the past five years.

Healthy Margins

Operating margin of 25.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.14.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Jun 2025 Revenue of $1.22B (+5.2% YoY); net profit $73.40M.
  • Trailing 12 Months Year-on-year growth — revenue -1.5%, earnings +128.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.0%, profit CAGR -2.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.04%
1 Year:-1.50%

Compounded Profit Growth

5 Years:-2.23%
1 Year:128.60%

Stock Price Performance

1 Year:+33.19%
6 Months:+34.80%
3 Months:+39.47%
1 Month:+0.85%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
$43.17 $72.47
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)65.54 · Neutral
Price Performance
1M+0.85%
3M+39.47%
6M+34.80%
1Y+33.19%
Valuation vs Sector

P/E of 103.47 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 10.0% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 103.5.
  • Earnings shrank at -2.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
103.47
Industry PE
25.17
Forward P/E
35.44
PEG Ratio
0.96
Book Value
$13.32
Price to Book
5.43
P/S
9.30
EV/EBITDA
31.13
Dividend Yield
0.44%

Growth (CAGR)

Revenue 5Y
10.04%
Profit 5Y
-2.23%
Revenue (YoY)
-1.50%
Earnings (YoY)
128.60%

Profitability & Returns

ROCE
4.29%
ROE
5.34%
ROA
7.45%
Profit Margin
9.05%
Op Margin
25.19%
Gross Margin
66.40%
EPS (Latest Qtr)
$0.32
EPS (TTM)
$0.70

Balance Sheet & Liquidity

Debt/Equity
0.14
Quick Ratio
2.80
Current Ratio
4.49
Debt
$290.32M
Total Assets
$2.55B
Current Assets
$608.30M
Working Capital
$432.45M

Ownership

Promoter Holding
0.33%
Chg in Prom Hold
-0.00%
FII / Inst Holding
115.16%
Chg in FII Hold
0.21%

Financial Snapshot

Enterprise Value
$11.29B
Total Revenue (TTM)
$1.21B
EBITDA
$366.04M
Free Cash Flow
$299.85M
Operating Cash Flow
$294.86M
Shares Outstanding
155.81M
Gross Margin
66.40%
Payout Ratio
45.71%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TECH Bio-Techne Corporation SPXR3KPHARMA 72.43 103.47 $11.29B 0.44% 4.29% 5.34% 10.04% -2.23%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2014Mar 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue ----------144.61M154.15M163.97M-162.97M174.51M184.86M-183.24M184.93M194.68M-204.20M224.25M243.55M257.72M269.28M290.38M269.65M271.58M294.15M276.94M272.60M303.43M289.46M297.03M316.18M286.56M295.88M311.42M
Gross Profit 75.74M79.38M75.39M81.59M89.99M-87.34M88.14M96.68M-97.87M101.83M110.26M-107.60M113.02M124.61M-118.41M121.40M130.06M-137.73M150.90M168.27M171.00M183.69M201.46M179.59M183.36M202.16M185.19M176.59M204.60M183.02M193.89M214.56M188.11M191.28M208.29M
Operating Income 34.58M39.43M31.03M36.02M43.53M-29.16M17.88M33.50M-26.03M24.15M43.08M-25.76M33.60M44.09M-33.33M36.99M47.79M-49.09M50.99M68.63M63.22M62.35M90.45M56.32M67.89M80.21M55.86M38.00M67.00M39.99M47.42M38.71M47.66M54.46M75.50M
Net Income 33.21M24.29M22.71M25.85M30.29M25.63M18.84M7.47M22.17M27.61M15.86M48.85M19.74M41.70M17.40M17.56M44.65M16.46M14.40M119.62M36.43M58.85M33.40M46.27M45.78M69.61M80.17M60.74M89.56M50.01M70.22M50.99M27.46M49.06M33.60M34.89M22.59M38.19M38.01M51.05M
Diluted EPS 0.890.650.610.690.810.690.500.200.590.740.421.290.521.070.450.451.150.420.373.020.921.480.831.151.121.690.490.370.550.310.430.310.170.310.210.220.140.240.240.32

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue 263.96M269.05M289.96M314.56M310.57M357.76M452.25M499.02M563.00M642.99M714.01M738.69M931.03M1.11B1.14B1.16B1.22B
Gross Profit 208.03M214.15M224.94M235.80M231.11M251.41M307.28M336.66M374.54M432.14M473.49M483.19M632.85M756.50M769.82M769.73M790.27M
Operating Income 150.78M156.33M163.06M166.21M158.47K159.75M147.02M150.59M120.58M136.18M146.72M157.42M237.30M296.59M298.94M206.69M102.25M
Net Income 105.24M109.78M112.30M112.33M112.56M110.95M107.73M104.48M76.09M126.15M96.07M229.30M140.41M272.05M285.26M168.10M73.40M
Diluted EPS 2.782.943.023.043.053.002.892.802.033.312.475.820.871.661.761.050.46

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets -472.00M518.82M617.67M719.32M778.10M862.49M1.06B1.13B1.56B1.59B1.88B2.03B2.26B2.29B2.64B2.70B2.56B
Current Assets --------------605.56M621.48M617.42M608.30M
Cash & Equivalents 166.99M160.94M94.14M77.61M116.67M163.79M318.57M54.53M64.24M91.61M121.99M100.89M146.62M199.09M172.57M180.57M151.79M162.19M
Inventory --------------141.12M171.64M179.73M189.45M
Receivables --------------194.55M218.47M241.39M206.88M
Total Liabilities --------------593.79M672.18M635.02M639.06M
Current Liabilities --17.02M18.19M35.75M32.08M26.39M39.77M54.15M135.52M79.51M101.98M106.67M152.28M176.02M128.51M159.38M175.85M
Long Term Debt --------------243.41M350.00M319.00M346.00M
Total Debt --------------325.97M454.96M419.54M444.06M
Total Equity 487.13M456.48M501.79M586.12M674.44M737.54M795.26M846.93M879.28M949.63M1.08B1.17B1.38B1.56B1.70B1.97B2.07B1.92B
Shares Outstanding --------------156.64M157.64M158.22M154.97M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow 111.32M111.26M127.19M126.75M123.56M--144.16M143.72M170.37M181.62M205.22M352.16M325.27M254.39M298.98M287.56M
Investing Cash Flow 21.28M-114.61M-114.19M-21.67M-31.20M---107.57M-305.95M-38.71M-336.80M27.09M-243.52M-96.85M-265.65M-203.03M-35.18M
Financing Cash Flow -119.44M-50.51M-36.29M-64.62M-44.68M---23.37M189.11M-99.19M134.38M-183.80M-62.55M-242.85M22.62M-122.40M-253.91M
Capital Expenditure -6.56M-4.64M-3.63M-6.02M-22.45M-13.82M-19.91M-16.90M-15.18M-20.93M-25.41M-51.74M-44.30M-44.91M-38.24M-62.88M-31.01M
Free Cash Flow 104.77M106.62M123.56M120.73M101.11M--127.26M128.54M149.43M156.21M153.47M307.86M280.36M216.15M236.10M256.55M
Net Change in Cash --------------14.43M11.36M-26.45M-1.53M
Share Buybacks 90.63M14.97M1.94M23.60M1.82M00--015.40M50.11M43.18M160.95M19.56M80.04M275.73M

Ratios (Annual)

Figures in %.

Metric Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % 78.8%79.6%77.6%75.0%74.4%70.3%67.9%67.5%66.5%67.2%66.3%65.4%68.0%68.4%67.7%66.4%64.8%
Operating Margin % 57.1%58.1%56.2%52.8%0.1%44.7%32.5%30.2%21.4%21.2%20.5%21.3%25.5%26.8%26.3%17.8%8.4%
Net Margin % 39.9%40.8%38.7%35.7%36.2%31.0%23.8%20.9%13.5%19.6%13.5%31.0%15.1%24.6%25.1%14.5%6.0%
ROE % 23.1%21.9%19.2%16.7%15.3%14.0%12.7%11.9%8.0%11.7%8.2%16.6%9.0%16.0%14.5%8.1%3.8%
ROCE % -31.2%27.2%24.3%0.0%19.1%14.4%14.0%8.5%9.0%8.2%8.2%11.2%14.0%11.9%8.1%4.3%

Shareholding Pattern

Insiders
0.33%
Institutions
115.16%
Public Float
115.54%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.94% 14.03M $1.01B
2 FMR, LLC 8.16% 12.79M $925.70M
3 Vanguard Capital Management LLC 6.52% 10.22M $739.31M
4 Goldman Sachs Group Inc 4.68% 7.34M $531.29M
5 HBK Investments L P 4.35% 6.83M $493.79M
6 Vanguard Portfolio Management LLC 4.15% 6.51M $470.74M
7 Morgan Stanley 4.07% 6.37M $461.21M
8 State Street Corporation 3.81% 5.98M $432.68M
9 Geode Capital Management, LLC 3.41% 5.35M $387.18M
10 Invesco Ltd. 3.18% 4.99M $360.77M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TECH

Google News Mon, 07 Sep 2026

UK Markets Brief: Is Computacenter Britain’s Next Tech Stock Hopeful? - Morningstar

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPS0hiLXVsT00zdXNoYm8ybVRITzJDdzFWdFF1ZllCODlDVGJjWThwbS1WTXRka091X2tabmRlMThhZW50QmZIUHc3NFV0eEdyN3pIRGNSRjh1STR6NEU3cEhyaW93YmtJNmhySHRwd3RSVmpmaWhEdU1SemUzWjVhTzVTOTVMMTJRdHd5Qn…

Google News Mon, 07 Sep 2026

Is Micron Technology Stock Running Out of Steam? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPd2xZYVBNQS1KNjVvQ0hQUDBKUERPTTFaazV3RkFlODhzSXlzMkNJVVlIVVo0Y1pQNVdjaC1KN3VpUDdOZ01WcERrSkd6MXJKckplTXFCOC1BbF9abTN0X2ZhZHd3VGNIaEVoNkRIQTI1WGJPRHR6VC1SUHltbG5BUFhPTlV2djBtM1l6TU…

Google News Mon, 07 Sep 2026

Cathie Wood buys $3.5 million of surging tech stock - thestreet.com

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPeEF3VDJxVFVad25WdUFYb296bElIc2xtMzA4WDFpVlpyckJoUUxJNEVxbk5WaXdEaElWWXpZU2EzVUtKUnNZYlFEUW80Z295THBJT1JXX0RmWHdDRzJOZjFaT3FPNjROUXdqTUVSX2xCZEdmWFRXMm9HSzJzQTc0eExiekE1NGo0dTVZSD…

Google News Mon, 07 Sep 2026

Stock Market Today: Tech Rally Surges in Asia, Kospi Soars, but European Stocks Struggle - barrons.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPai1LaXZJdHN4T01NT1FUdEQ5ZnJjdWhNU3NoSk5pYnJRUGlPdk5faFp1TUc1VTFwZVloZm5ESzl5eHVnYzdyNExtbnNfbGYtcUNadHVfaU5ZV3p2cDFJNUNqQjNlUDlLeURTTnJyYzhNbFl2a3RYUDJpVjVMRE16QS0xeXhrQWVTbWlYQX…

Google News Mon, 07 Sep 2026

Is Adobe's Stock Heading for $300? - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPVmpuMi1GQkNiSlhtaTUweFNlVHE5WFNabjZoQURWZ01oNEhEWG9kUWlrdXBQMVVFRmtBR25OazhmZExDeHQ4X1hmNHVVeWoyM2VOdUhBTU12NHVLX0NfY3R0aTV5WnNLZ0xYbDBDMDBrYTUzQmFGa050WFJyMlBNRQ?oc=5" target="_…

Google News hu, 13 Aug 2026

Tech stock ideas - Fidelity Investments

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQX1lsbkQ3VWtyM1ZwemNiQkU5ck00SjF4bm9wdzlmczJSaEIzbV95ZzRaNUZJZ3FOWG94T04tNmpKZHUyb2cwVTNVS1Uzay1DU0FlekM5YmZWNHA3QXdqYnJONTlDb0pKVnRqRkpLcTMyU1NKcVIxalBUbmZCR0diVA?oc=5" target="_…

TECH — Frequently Asked Questions

What is the current share price of Bio-Techne Corporation (TECH)?

As of 2026-09-07 16:24 PDT, Bio-Techne Corporation (TECH) trades at $72.43 on NasdaqGS. Its 52-week range is $43.17 to $72.47.

What is the market capitalisation of TECH?

Bio-Techne Corporation (TECH) has a market capitalisation of $11.29B on NasdaqGS.

What is the P/E ratio of TECH?

TECH trades at a trailing price-to-earnings (P/E) ratio of 103.47. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.43.

Does TECH pay a dividend?

Bio-Techne Corporation (TECH) currently offers a dividend yield of 0.44%.

What is the return on equity (ROE) of TECH?

TECH has a return on equity (ROE) of 5.34%. Its return on capital employed (ROCE) is 4.29%.

Is TECH a good stock to buy?

This page provides a data-driven analysis of Bio-Techne Corporation (TECH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space